Obsidian Therapeutics Inc. raised $49.5m in Series A venture capital to develop its technology for inserting a synthetic tag into chimeric antigen receptor T cell (CAR-T) therapies so that the they can be activated or deactivated as needed for efficacy or safety.
That's just one of three initial uses for Obsidian's technology that CEO Michael Gilman described in an interview with Scrip...






